Theralase Advances Anti-Cancer Technology Platform
03 Avril 2014 - 1:00PM
Access Wire
TORONTO, ON / ACCESSWIRE / April 3, 2014 / Theralase
Technologies Inc. ("Theralase") (TSXV: TLT) (TLTFF: OTCBB)
announced today that it has advanced its anti-cancer technology
platform through an executed research agreement with Acadia
University ("Acadia"). Under the terms of the agreement, Acadia
will supply initial quantities of Theralase's lead Photo Dynamic
Compounds (PDCs) and the Standard Operating Procedures (SOPs) of
how to synthesize them.
The lead PDCs will be used by Theralase to commence toxicity
analysis and manufacturing ramp up via Contract Manufacturing
Organization (CMO); both mandatory prerequisites in the evolution
towards an approved Investigational New Drug (IND) application from
the FDA and Health Canada. With larger quantities of the PDCs in
hand and an approved IND; Theralase would be in the position to
commence a Phase 1/2a human clinical trial for the lead indication
of bladder cancer, as early as 1Q2015.
The lead PDCs have advanced towards international patent
protection under a filed Patent Cooperation Treaty (PCT)
application. Once approved at this phase, the Company plans to
provide wide spread patent coverage of the PDCs across numerous
countries during the national phase.
Dr. Sherri McFarland, Professor of Chemistry at Acadia
University, the originator of the PDCs under worldwide exclusive
licence to Theralase stated, "I am truly excited to work with
Theralase in the development of these PDCs and be associated with
their lead scientists and clinical oncologists to develop the next
generation of anti-cancer technology. From the raw research I have
observed, this technology has the potential to not only destroy one
type of cancer, but many. I am convinced that this technology has
the opportunity to go mainstream as a primary treatment in the
destruction of cancer, within the next few years."
Dr. David MacKinnon, Dean, Research and Graduate Studies at
Acadia University stated, "We are pleased to have partnered with
Theralase in the development of these PDCs for the destruction of
cancer. It is rewarding to advance research originally developed in
our chemistry labs from conception through to commercialization
knowing that it may one day be a cure for cancer."
Dr. Arkady Mandel, Chief Scientific Officer of Theralase stated
that, "Sherri's strong background as a medicinal chemist and
specialist in photochemistry, coupled with my scientific and
medical knowledge as to how laser light interacts at the molecular
and cellular level, will bring a new platform of cutting-edge
anti-cancer technologies to the forefront within the next few
years."
Roger Dumoulin-White, President and CEO of Theralase stated
that, "I am delighted that Acadia has partnered with Theralase in
the commercialization of technology that may provide a new front
line treatment for cancer in the not too distant future. With good
partners, disruptive technologies are born, which can make marked
impacts on devastating diseases such as cancer, in our lifetime. I
am humbled to be part of the process."
About Theralase Technologies Inc.
Theralase Technologies Inc. designs, manufactures and markets
patented, superpulsed laser technology used in eliminating pain and
destroying cancer. Theralase technology is safe and effective in
eliminating pain, reducing inflammation and accelerating tissue
regeneration of numerous nerve, muscle and joint injuries.
Theralase is actively developing patented technology that is able
to target and destroy cancers, bacteria and viruses when light
activated.
Additional information is available at www.theralase.com and
www.sedar.com.
This press release contains forward-looking statements, which
reflect the Company's current expectations regarding future events.
The forward-looking statements involve risks and uncertainties.
Actual results could differ materially from those projected herein.
The Company disclaims any obligation to update these
forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchanges) accepts responsibility for the adequacy or
accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
Theralase Technologies Inc.
1.866.THE.LASE (843-5273)
416.699.LASE (5273) ext. 225
rwhite@theralase.com
David McKinnon
Dean, Research and Graduate Studies
Acadia University
1.902.585.1498
david.mackinnon@acadiau.ca
SOURCE: Theralase Technologies Inc.
Theralase Technologies (TSXV:TLT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Theralase Technologies (TSXV:TLT)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024